Corcept Therapeutics (NASDAQ:CORT) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Corcept Therapeutics (NASDAQ:CORT) had its target price boosted by stock analysts at Canaccord Genuity Group from $100.00 to $110.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price target points to a potential upside of 192.55% from the stock’s current price.

A number of other equities analysts have also recently weighed in on the company. UBS Group started coverage on Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price target for the company. Zacks Research cut shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. HC Wainwright decreased their target price on shares of Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Finally, Wolfe Research raised shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $77.67.

Corcept Therapeutics Trading Down 2.4%

Shares of CORT opened at $37.60 on Thursday. Corcept Therapeutics has a 12 month low of $28.66 and a 12 month high of $117.33. The stock’s 50-day moving average is $37.53 and its two-hundred day moving average is $60.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.92 and a quick ratio of 2.85. The stock has a market cap of $4.00 billion, a PE ratio of 45.85 and a beta of 0.29.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). The company had revenue of $202.13 million during the quarter, compared to analyst estimates of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. Corcept Therapeutics’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.26 EPS. Equities analysts forecast that Corcept Therapeutics will post 1.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, Director G Leonard Baker, Jr. bought 100,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, March 17th. The stock was bought at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the purchase, the director owned 1,146,631 shares in the company, valued at $37,999,351.34. This represents a 9.55% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Joseph K. Belanoff sold 26,198 shares of the firm’s stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the sale, the chief executive officer directly owned 2,918,326 shares of the company’s stock, valued at $146,120,582.82. The trade was a 0.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 86,198 shares of company stock worth $3,552,769 in the last 90 days. 20.80% of the stock is owned by corporate insiders.

Institutional Trading of Corcept Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Torren Management LLC acquired a new position in Corcept Therapeutics during the 4th quarter worth $25,000. Advisory Services Network LLC bought a new stake in shares of Corcept Therapeutics in the 3rd quarter worth about $25,000. Clearstead Advisors LLC raised its stake in shares of Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 193 shares in the last quarter. Atlas Capital Advisors Inc. acquired a new stake in shares of Corcept Therapeutics in the 4th quarter valued at about $31,000. Finally, Hantz Financial Services Inc. lifted its position in shares of Corcept Therapeutics by 113.7% during the fourth quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 524 shares during the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer is a material commercial catalyst that triggered the earlier sharp rally; approval creates a new revenue pathway and is the primary reason investors re‑rated the stock this week. FDA approval report
• Positive Sentiment: Broker/analyst support: Wolfe Research upgraded CORT (from underperform to peer‑perform) and other brokers (Truist, Canaccord) have issued bullish/strong‑buy views or raised targets, which can sustain buying interest as the market models new sales upside. Wolfe Research upgrade
• Neutral Sentiment: Market structure/volatility: trading halts and large intraday prints accompanied the approval-driven move — expect continued high volume and price swings as investors reprice expectations for launch and uptake. Market reaction coverage
• Neutral Sentiment: Consensus/ratings mix: some outlets show a “moderate buy” brokerage consensus; analysts remain mixed on valuation as the market weighs launch potential vs. prior execution and study data. Broker consensus report
• Negative Sentiment: Legal risk: multiple law firms have filed shareholder alerts and class actions alleging that Corcept misled investors about regulatory issues and patent matters; these suits (and the referenced FDA rejection / federal court patent loss claims) create potential liability, discovery risk and distraction for management. Hagens Berman class‑action alert
• Negative Sentiment: Insider selling: a recent disclosed sale by an insider reduced holdings significantly; while not proof of negative outlook, such sales can weigh on sentiment when paired with litigation headlines. Insider sale filing
• Negative Sentiment: Analyst divergence / forecast cuts: some firms have tempered long‑term estimates or issued cautious notes (e.g., a pessimistic forecast from HC Wainwright in recent coverage), underscoring uncertainty around peak sales and reimbursement. HC Wainwright coverage

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.